Your fact-checks will appear here
American biotechnology company
Recent reporting and public-health documents show no consistent evidence that the updated 2024–25 or 2025–26 COVID-19 vaccines introduced wholly new, common side effects; surveillance and news coverag...
Public, consumer-facing lot‑number lookup tools exist for some COVID‑19 vaccines (for example Moderna’s Vial Lookup and manufacturer/Janssen checkers), but Pfizer (Comirnaty/BNT162b2) does not maintai...
Large surveillance studies and safety summaries show different rare long‑term risks for the Janssen (J&J) adenovirus vaccine versus mRNA vaccines: J&J has been associated with rare thrombosis with thr...
Pfizer and Moderna mRNA vaccines produce (injection-site pain, fatigue, headache, fever) that are generally mild and resolve in days, with likely due to a higher mRNA dose . Rare serious events differ...
Clinical-trial and public-health reporting consistently list local pain at the injection site, fatigue, headache, muscle aches and chills as the most commonly reported side effects after Pfizer’s COVI...
Vaccine manufacturers do make from vaccines, but the scale and context vary by company, product, and time period; COVID‑19 vaccines produced especially large revenues and profits for major firms durin...
Clinical surveillance through 2022–2025 finds , with Janssen linked more to thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barré syndrome (GBS), and mRNA vaccines showing higher signals ...
Clinical-trial and post‑authorization reports for the 2024–2025 updated COVID vaccines show predictable, mostly short‑lived reactions — injection‑site pain/tenderness, fatigue, muscle aches, fever, he...
Public records and patent databases show that Anthony S. Fauci is listed as an inventor on multiple patents and patent applications, mainly related to HIV biology and therapeutics assigned to the U.S....
Available reporting links Johnson & Johnson’s (J&J/Janssen) adenovirus‑vector COVID‑19 vaccine to a rare syndrome—thrombosis with thrombocytopenia syndrome (TTS)—with roughly 57–60 reported U.S. cases...
Dr. David E. Martin is presented in the provided materials as a researcher who links historical coronavirus cultivation, patents, and pandemic-era policy decisions to suspicions about COVID-19 origins...
mRNA COVID-19 vaccines can trigger short-lived changes in immune markers and—in rare cases—cause inflammatory conditions such as myocarditis; major public-health reviews and cohort studies find no sus...
Available reporting shows Anthony Fauci did not personally pocket large pandemic-era royalties tied to NIH-held patents; he told lawmakers he receives “about $120 a year” from a decades-old monoclonal...
Large safety reviews and surveillance systems report that most consequences of Pfizer and Moderna mRNA COVID-19 vaccines are short‑lived (local pain, fatigue, fever) but rare serious events have been ...
The body of evidence as of late 2025 does not establish a causal link between the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) and increased cancer risk; surveillance and systematic reviews show common...
Available surveillance and regulatory reports show the 2023–2024 mRNA COVID vaccines had estimated myocarditis/pericarditis incidence of roughly 8 cases per million doses overall and higher rates in y...
The evidence assembled shows that the Johnson & Johnson (Ad26.COV2.S) vaccine and mRNA vaccines (Pfizer-BioNTech, Moderna) have broadly favorable safety profiles but have been observed in post‑licensu...
Booster doses of the mRNA COVID-19 vaccines tend to cause local and systemic reactions that are generally similar in type but not more severe than reactions seen after the primary series, with most tr...
Pfizer’s COVID-19 mRNA vaccine uses lipid nanoparticles — a nanotechnology delivery system — and that approach is credited with enabling real-world protection measured across billions of doses (Pfizer...
Available studies and regulatory summaries show myocarditis after COVID-19 vaccination is rare, concentrates in males aged ~12–24 and most often occurs within days of a second mRNA dose; FDA cites ~27...